Business Context and Reporting Period
Mink Therapeutics, Inc. (INKT) filed a Form 8-K on December 8, 2025, to report a late disclosure of financial results for the quarter ended September 30, 2025. The Company, an emerging growth company incorporated in Delaware, originally issued a press release and hosted a conference call on November 14, 2025, but inadvertently failed to file the required Current Report at that time.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves solely as a procedural notice to furnish the press release and conference call transcript containing these details as Exhibits 99.1 and 99.2.
Material Changes
The Company explicitly states there are no revisions to the financial results presented in the November 14, 2025 press release and conference call. No material changes to previously reported figures are indicated in this filing.
Guidance, Outlook, and Risks
Management commentary, guidance, and risk factors are contained within the furnished press release and conference call transcript, which are not included in the text of this 8-K. The filing notes that the information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 financial figures.
- Review Exhibit 99.2 (Conference Call Transcript) for management commentary and outlook.
- Verify the Company's cash runway and burn rate given the lack of revenue disclosure in the summary text.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.